1 / 234 国航远洋 920571 福建国航远洋运输（集团）股份有限公司 官微二维码 年度报告 （如有） 可视化年报 （如有） 2025 2 / 234 3 / 234 致投资者的信 于全球变局中守正，穿越周期的确定性 2025 年，全球经贸格局复杂多变，市场周期与宏观波动交织，不确定性成为常态。而航运作为 全球贸易流通的核心载体，凭借不可替代的刚性需求，始终是不确定中最具韧性的确定性力量，支 撑我们穿越风浪、行稳致远。 于变局中守正，于波动中前行，是我们不变的坚守。2025 年，公司坚持高质量发展主线，持续 强化市值管理与投资者关系维护；积极践行绿色 ESG 可持续发展，推进低碳运力与智能船舶建设， 以绿色航运赋能长期价值，与全体股东共享成长成果。 2025 年，我们聚焦高质量发展，经营业绩"稳"中有"进"。 公司聚焦国际国内大宗航运，在全球经贸风云变幻、行业周期波动的复杂环境下，实现经营业 绩"稳"中有"进"、质效双升。2025 年，公司实现营业收入 9.97 亿元，同比增长 6.51%；归属 于上市公司股东的净利润 2771.34 万元，同比大幅增长 22.28%。公司以稳固的航线布局、高效的运 营 ...

广东电力发展股份有限公司 2025 年年度报告全文 广东电力发展股份有限公司 2025 年年度报告 2026 年 3 月 广东电力发展股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人郑云鹏、主管会计工作负责人刘维及会计机构负责人（会计 主管人员）蒙飞声明：保证本年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 | 未亲自出席董事 | 未亲自出席董事 | 未亲自出席会议 | 被委托人姓名 | | --- | --- | --- | --- | | 姓名 | 职务 | 原因 | | | 李方吉 | 董事 | 因事 | 郑云鹏 | 本年度报告涉及公司未来发展战略、经营计划等前瞻性陈述，不构成公 司对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。 本公司主营业务为电力项目、新能源项目的投资、建设和经营管理，关 于公司未来发 ...

深圳市同洲电子股份有限公司 2025 年年度报告全文 深圳市同洲电子股份有限公司 2025 年年度报告 【2026 年 3 月】 1 深圳市同洲电子股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人张纯银、主管会计工作负责人由鑫堂及会计机构负责人（会 计主管人员）孙贺声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 公司可能存在市场风险、管理人员变动风险、技术风险、汇率风险等， 敬请广大投资者注意投资风险。公司面临的风险与应对措施详见本报告第三 节"管理层讨论与分析"的相关内容。 公司经本次董事会审议通过的利润分配预案为：以 752439694 为基数， 向全体股东每 10 股派发现金红利 0 元（含税），送红股 ...

Technological Advancements - The company has established a comprehensive "启元生态" that integrates various large models to empower clinical practices, marking a significant leap in its technological capabilities [4]. - The new SEMS platform in the in vitro diagnostics field has achieved industry-leading "mass spectrometry-level" performance, enhancing detection capabilities significantly [5]. - The high-sensitivity cardiac troponin hs-cTnI has improved interference resistance by 20 times, reducing false positive or negative risks from 2-3 cases per week to 2-3 cases per year [6]. - The company is developing a self-regulating closed-loop anesthesia system, integrating various medical devices to enhance operational efficiency [6]. - The "Rui Zhi Ecological" solution has been upgraded to integrate "equipment + IT + AI" for improved data integration and clinical utility [83]. - The introduction of a new blood cell analyzer is anticipated to capture a significant share of the diagnostics market, with expected sales of $200 million in the first year [37]. - The AI technology innovations include the NN-PBRTQC system, which reduces sample size requirements for error detection by 67% and decreases false alarms to 1/100 of previous levels [137]. - The MT 8000C smart coagulation workflow system features an "Eagle Eye" quality check system that monitors sample quality comprehensively, aiming to automate and standardize coagulation testing [141]. - The company launched the MN2880 automatic nucleic acid purification and real-time fluorescence PCR analysis system, achieving results in 40 minutes for the first sample and 6 results every 6 minutes, enhancing diagnostic efficiency [148]. - The company achieved a breakthrough in ultrasound imaging with the launch of the world's first integrated super-resolution imaging technology, enhancing diagnostic capabilities from millimeter to micrometer resolution [174]. Market Expansion - The company’s products are now sold in over 190 countries and regions, covering 87 of the top 100 hospitals globally, with 9 product categories holding the number one market share in China [8]. - The company has established 64 overseas subsidiaries in about 40 countries, with over 90% of its 3,000 overseas employees being locals [9]. - Mindray is focusing on expanding its market presence in Latin America and Southeast Asia, aiming for a 20% increase in market share in these regions over the next two years [34]. - The company is expanding its market presence in Asia, targeting a 25% increase in market share by 2025 [36]. - The company plans to enhance its localization strategy and high-end customer penetration in international markets, particularly in Europe, which saw a 17% growth [60]. - The company has expanded its international strategic customer base, breaking through nearly 90 key clients, including 17 of the top 100 hospitals globally [118]. - In North America, the company has covered approximately 80% of IDN medical systems and over 2,100 IDN hospitals, with nearly 35% using two or more product combinations [119]. Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the last quarter, reaching RMB 5 billion [33]. - Mindray's profit distribution plan for 2025 includes a cash dividend of 3.10 CNY per 10 shares, based on a total share capital of 1,212,441,394 shares [19]. - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion in Q3 2023 [35]. - The company achieved operating revenue of CNY 3,328,215.94 million, a decrease of 9.38% year-on-year [59]. - Net profit for the period was CNY 845,147.14 million, down 28.01% compared to the previous year [59]. - The company's revenue for 2025 was CNY 33.28 billion, a decrease of 9.38% compared to CNY 36.73 billion in 2024 [45]. - Net profit attributable to shareholders for 2025 was CNY 8.14 billion, down 30.28% from CNY 11.67 billion in 2024 [45]. Research and Development - The company is investing heavily in R&D, with a budget allocation of RMB 800 million for new product development in the upcoming fiscal year [34]. - The R&D budget was increased by 30%, focusing on innovative diagnostic solutions and minimally invasive surgical technologies [37]. - The company maintained a high R&D investment of 392.89 million yuan, accounting for 11.80% of its revenue, to support continuous innovation and product development [134]. - The company has applied for a total of 12,983 patents, with 9,399 being invention patents, reflecting its commitment to innovation and intellectual property protection [134]. Strategic Initiatives - The company is collaborating with global partners to enhance medical standards and training, transitioning from a medical device supplier to a strategic partner in global healthcare systems [11]. - Mindray aims to build a resilient global medical collaboration network, integrating products and solutions into local healthcare systems [13]. - The company is exploring potential acquisitions to enhance its technological capabilities and expand its product portfolio, with a focus on companies in the medical device sector [34]. - The company has established a dedicated division for electrophysiology, successfully launching PFA and RFA products for clinical applications in atrial fibrillation [104]. - The company has successfully deployed the "Qiyuan" specialized large model in top hospitals in China, enhancing product competitiveness and brand influence [82]. Product Development - Mindray plans to launch three new medical devices by the end of Q2 2024, targeting a 10% increase in sales from these products [34]. - The company launched 14 new in vitro diagnostic products, including various assay kits and automated analysis systems, aiming to support sustainable growth in the in vitro diagnostic business [135]. - The company introduced a micro-invasive surgical solution that integrates ultrasound imaging with optical endoscopy, improving operational efficiency and clinical experience during surgeries [172]. - The company launched several new products in the medical imaging field, including the Resona/Nuewa I10 series high-end color Doppler ultrasound and the DigiEye U series high-end suspended DR systems [166]. Quality and Compliance - Mindray's commitment to quality is reflected in its adherence to international standards such as ISO 13485 and ISO 9001, ensuring compliance with regulatory requirements [34]. - The company is committed to adhering to international standards, including ISO 37001:2016, to enhance its anti-bribery management system [35]. Healthcare Accessibility - The company remains committed to its mission of providing affordable and quality healthcare services globally [55]. - The company is focusing on integrating AI and digital solutions to improve healthcare accessibility and efficiency [56]. - The company is focusing on digital transformation in healthcare, leveraging AI and innovative medical product development [39].

广东美联新材料股份有限公司 2025 年年度报告全文 广东美联新材料股份有限公司 2025 年年度报告 2026 年 3 月 1 广东美联新材料股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人黄伟汕、主管会计工作负责人易东生及会计机构负责人(会计 主管人员)刘志裕声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 一、业绩大幅下滑或者亏损的具体原因 1、报告期内，由于市场竞争激烈和需求变化等因素的影响，公司精细化 工主要产品销量和单价下降，毛利率同比下降幅度较大。 2、基于谨慎性原则，公司对存在减值迹象的相关资产计提了相应的减值 准备，本年度发生各项资产减值准备合计 5,584.88 万元，其中存货跌价准备 3,380.21 万元，固定资产减值准备 415.43 万元，商誉减值准备 1,564.08 万 元，应收款项坏账准备 225.16 万元。 二、主营业务、核心竞争力、主 ...

中远海运发展股份有限公司2025 年年度报告 公司代码：601866 公司简称：中远海发 中远海运发展股份有限公司 2025 年年度报告 1 / 249 中远海运发展股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司董事长张铭文、执行董事及总经理王坤辉、总会计师胡海兵及会计机构负责人（会计主 管人员）徐飞声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2025年末期拟以实施权益分派股权登记日登记的总股本扣除届时回购专用账户上股份数 后的股本为基数，向全体股东派发末期股息每10股0.15元（含税），剩余未分配利润全部结转下 年度。本次末期利润分配方案须经公司股东会批准后实施。 截至报告期末，母公司存在未弥补亏损的相关情况及其对公司分红等事项的影响 □适用 √不适用 六、 前瞻性陈 ...

苏州和林微纳科技股份有限公司2025 年年度报告 公司代码：688661 公司简称：和林微纳 苏州和林微纳科技股份有限公司 2025 年年度报告 1 / 245 苏州和林微纳科技股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 公司已在本报告中描述公司面临的风险，敬请查阅本报告第三节"管理层讨论与分析"中 "风 险因素"相关内容，请投资者予以关注。 四、公司全体董事出席董事会会议。 五、 天衡会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、公司负责人骆兴顺、主管会计工作负责人王军委及会计机构负责人（会计主管人员）万俊 声明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2025年度利润分配及资本公积转增股本方案为：公司拟向全体股东每10股派发现金红利 0.8元（含税）。截至2025年12月31日，公司总股本151, ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the fiscal year 2025, representing a year-over-year growth of 15%[16]. - The company's operating revenue for 2025 reached ¥2,142,091,293.26, representing a year-on-year increase of 75.65% compared to ¥1,219,538,223.81 in 2024[25]. - The net profit attributable to shareholders for 2025 was ¥172,991,828.80, a significant turnaround from a loss of ¥197,216,906.42 in 2024[25]. - Basic earnings per share for 2025 were ¥1.30, compared to a loss of ¥1.50 in 2024, indicating a substantial improvement[24]. - The net cash flow from operating activities increased by 109.33% to ¥147,770,952.44 in 2025, up from ¥70,591,393.37 in 2024[25]. - The gross margin for the last quarter was reported at 45%, a slight increase from 42% in the previous quarter[16]. - The comprehensive gross margin for 2025 was 46.64%, with signal chain chips achieving a gross margin of 50.53% and power management chips at 39.22%[67]. - The company reported a significant increase in tax and additional charges by 128.81% due to higher sales[131]. - The company achieved a revenue of 379 million yuan from the acquisition of Chuangxinwei, with a net profit of 87.53 million yuan after excluding share-based payment expenses, reflecting a year-on-year increase in gross margin[88]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.55 CNY per 10 shares, totaling approximately 21.19 million CNY, which represents 12.25% of the net profit attributable to shareholders for the year[4]. - The board of directors has approved the profit distribution plan, pending approval from the shareholders' meeting[6]. - As of December 31, 2025, the company's distributable profits amount to approximately 1.17 billion CNY[4]. Research and Development - The company is investing RMB 200 million in R&D for new technologies, focusing on signal improvement capabilities[16]. - The R&D expenditure as a percentage of operating revenue decreased to 27.46% in 2025 from 47.32% in 2024, a reduction of 19.86 percentage points[24]. - The company has filed a total of 676 invention patents and 171 utility model patents, with 217 effective invention patents and 112 utility model patents granted by the end of the reporting period, establishing a strong technological barrier[91]. - The company achieved a total R&D investment of ¥588,188,800.29, representing a 1.93% increase from the previous year's investment of ¥577,057,125.73[105]. - R&D investment accounted for 27.46% of total revenue, a decrease of 19.86 percentage points compared to the previous year[105]. Market Expansion and Strategy - The company is exploring strategic acquisitions to enhance its product portfolio and market reach[16]. - Market expansion efforts include entering the European market, targeting a 10% market share within two years[16]. - The company aims to enhance its product line and application scenarios in the analog and mixed-signal chip sectors, leveraging its R&D capabilities and customer resources[54]. - The company is focusing on high-performance and low-power designs to meet the demands of AI, smart driving, and industrial automation[55]. - The company is focusing on expanding its product line in the automotive sector, particularly in battery management systems for electric vehicles[40]. Corporate Governance - The company has established a governance structure that includes a board of directors and an audit committee, ensuring compliance with legal requirements and enhancing operational efficiency[180]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[182]. - The company received an A-level rating for its information disclosure work from the Shanghai Stock Exchange for the 2024-2025 period[183]. - The company has implemented a market value management system to ensure investor interests are considered in major decisions[185]. Risks and Challenges - The company has outlined potential risks associated with forward-looking statements, advising investors to exercise caution[7]. - The company faces risks related to the need for continuous technological innovation to maintain competitiveness in the integrated circuit design industry[116]. - The company is exposed to risks from high supplier concentration, which could impact procurement costs and profitability[119]. - International trade tensions may restrict the company's access to semiconductor technologies and services, potentially impacting operations and revenue[125]. Product Development and Innovation - The company has developed automotive-grade analog front ends with a collection accuracy of ±3mV and supports dual-channel communication, meeting ISO26262 safety standards[40]. - The company is focusing on expanding its product offerings in the smart power module sector, leveraging proprietary technology to enhance efficiency in personal care and small appliance markets[112]. - The company is enhancing its semiconductor technology to reduce input noise and improve power supply rejection ratios, which is critical for high-performance applications[109]. - The company is actively pursuing new ventures, including the establishment of Suzhou Xingshan Management Consulting Partnership, which is set to launch in June 2024[195]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting a 10% increase from the previous quarter[190]. - The company is actively engaging with investors through various channels, including performance briefings and investor hotlines[185]. Financial Management - The company has implemented a supply chain management system to enhance operational efficiency and reduce inventory accumulation[47]. - The company has a strong focus on R&D in high-performance integrated circuit products, covering various applications including industrial, new energy, automotive, communication, consumer electronics, and healthcare[36]. - The company has established a comprehensive sales model combining both distribution and direct sales to meet customer demands effectively[47].

公司代码：688521 公司简称：芯原股份 芯原微电子（上海）股份有限公司 2025 年年度报告 1 / 334 芯原微电子（上海）股份有限公司2025 年年度报告 芯原微电子（上海）股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司上市时未盈利且尚未实现盈利 □是 √否 三、重大风险提示 公司已在报告中详细描述可能存在的相关风险，敬请查阅本报告"第三节 管理层讨论与分析" 中"四、风险因素"部分内容。 四、公司全体董事出席董事会会议。 五、德勤华永会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、公司负责人Wayne Wei-Ming Dai（戴伟民）、主管会计工作负责人赵春蓉及会计机构负责人 （会计主管人员）沙乐声明：保证年度报告中财务报告的真实、准确、完整。 七、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 因公司合并报表累计未分配利润为-29.44 亿元，母公司财务报表累计未分配利润为-10.71 亿 元，且经营性现金 ...

广东香山衡器集团股份有限公司 2025 年年度报告全文 证券代码：002870 证券简称：香山股份 公告编号：2026-009 广东香山衡器集团股份有限公司 2025 年年度报告 2026 年 3 月 1 广东香山衡器集团股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人刘玉达、主管会计工作负责人尤佳及会计机构负责人（会计 主管人员）尤佳声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所述的相关发展规划、方向及项目计划、目标等未来预测，均为 公司根据市场情况和实际发展需要而制定的经营计划，在实际实施过程中， 存在中止、变更等各种不确定因素，因此均不构成公司对投资者的业绩承诺， 请广大投资者对此保持足够的风险意识，并应当理解经营计划与业绩承诺之 间的差异。 公司可能面临的风险，敬请查阅本报告第三节"管理层讨论与分析"之十 一"公司未来发展的展望"所描述的风险内容，请投资者 ...